Lumicitabine: Clinical Trials

4 trials of Lumicitabine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 completed, 1 withdrawn. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Terminated 2, Completed 1, Withdrawn 1

Follow Lumicitabine: new trials by email Literature Review of Lumicitabine trials Research Report on Lumicitabine

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus
Lumicitabine, Placebo - Metapneumovirus
Phase 2WithdrawnJanssen Research & Development, LLC2018-11-052018-11-15
A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection
Lumicitabine, Placebo - Respiratory Syncytial Virus Infections
Phase 2CompletedJanssen Research & Development, LLC72018-01-052021-04-13
A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus
Lumicitabine, Placebo - Respiratory Syncytial Viruses
Phase 2TerminatedJanssen Research & Development, LLC72017-11-242019-12-23
Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus
lumicitabine, Placebo - Respiratory Syncytial Viruses
Phase 2TerminatedJanssen Research & Development, LLC492016-10-252019-12-24

Conditions studied

Respiratory Syncytial Virus Infections (1)

Sponsors

Janssen Research & Development, LLC (4)

Countries

Japan (4)  ·  Poland (3)  ·  United States (3)  ·  Argentina (2)  ·  Australia (2)  ·  Belgium (2)  ·  Brazil (2)  ·  Bulgaria (2)  ·  Canada (2)  ·  France (2)  ·  Malaysia (2)  ·  Netherlands (2)  ·  South Korea (2)  ·  Spain (2)  ·  Sweden (2)

Results publications

PMID 37467213

NIH funding

2016 (2), 2017 (2)